Acadia Pharmaceuticals | ACAD - Operating Profit


Acadia Pharmaceuticals reported $37.84M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
ALKERMES USD -65.93M 17.65M Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Cara Therapeutics USD -7.05M 1.11M Mar/2026
Corcept Therapeutics USD 41.3M 90.9M Jun/2026
Cytokinetics USD -179.17M 2.05M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Incyte USD -707.47M 1.41B Sep/2026
J&J USD 6.47B 1B Sep/2026
Moderna USD -815M 573M Jun/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Prothena USD 25.79M 53M Mar/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Vertex Pharmaceuticals USD 1.27B 129.9M Jun/2026